Stock Track | CorMedix Soars 9.47% Pre-Market on Strong Q3 Results and Raised Guidance

Stock Track11-12

Shares of CorMedix Inc. (CRMD) surged 9.47% in pre-market trading on Wednesday following the release of its impressive third-quarter 2025 financial results and an upward revision of its full-year guidance.

The biopharma company reported a third-quarter earnings per share (EPS) of $1.26, significantly beating the analyst consensus estimate of $0.65. Net income for the quarter stood at $108.6 million, nearly doubling the expected $54.7 million. CorMedix's strong performance was largely driven by higher-than-anticipated sales of its flagship product, DefenCath, which contributed $88.8 million to the quarter's net revenue of $104.3 million.

In light of the robust quarterly performance, CorMedix raised its full-year 2025 pro forma net revenue guidance to a range of $390 million to $410 million. The company also increased its 2025 pro forma adjusted EBITDA guidance to between $220 million and $240 million. This optimistic outlook, coupled with the strong Q3 results, has fueled investor enthusiasm, leading to the significant pre-market stock price jump.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1123083935?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 20:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1123083935","market":"us","top_or_hot":-1,"title":"Stock Track | CorMedix Soars 9.47% Pre-Market on Strong Q3 Results and Raised Guidance","media":"Stock Track","content":"<p>Shares of CorMedix Inc. (CRMD) surged 9.47% in pre-market trading on Wednesday following the release of its impressive third-quarter 2025 financial results and an upward revision of its full-year guidance.</p>\n\n<p>The biopharma company reported a third-quarter earnings per share (EPS) of $1.26, significantly beating the analyst consensus estimate of $0.65. Net income for the quarter stood at $108.6 million, nearly doubling the expected $54.7 million. CorMedix's strong performance was largely driven by higher-than-anticipated sales of its flagship product, DefenCath, which contributed $88.8 million to the quarter's net revenue of $104.3 million.</p>\n\n<p>In light of the robust quarterly performance, CorMedix raised its full-year 2025 pro forma net revenue guidance to a range of $390 million to $410 million. The company also increased its 2025 pro forma adjusted EBITDA guidance to between $220 million and $240 million. This optimistic outlook, coupled with the strong Q3 results, has fueled investor enthusiasm, leading to the significant pre-market stock price jump.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | CorMedix Soars 9.47% Pre-Market on Strong Q3 Results and Raised Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | CorMedix Soars 9.47% Pre-Market on Strong Q3 Results and Raised Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-12 20:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of CorMedix Inc. (CRMD) surged 9.47% in pre-market trading on Wednesday following the release of its impressive third-quarter 2025 financial results and an upward revision of its full-year guidance.</p>\n\n<p>The biopharma company reported a third-quarter earnings per share (EPS) of $1.26, significantly beating the analyst consensus estimate of $0.65. Net income for the quarter stood at $108.6 million, nearly doubling the expected $54.7 million. CorMedix's strong performance was largely driven by higher-than-anticipated sales of its flagship product, DefenCath, which contributed $88.8 million to the quarter's net revenue of $104.3 million.</p>\n\n<p>In light of the robust quarterly performance, CorMedix raised its full-year 2025 pro forma net revenue guidance to a range of $390 million to $410 million. The company also increased its 2025 pro forma adjusted EBITDA guidance to between $220 million and $240 million. This optimistic outlook, coupled with the strong Q3 results, has fueled investor enthusiasm, leading to the significant pre-market stock price jump.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRMD","symbol_name":"CorMedix Inc.","start_time":0,"source_url":"","article_id":"1123083935","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1123083935","pubTimestamp":1762951719,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of CorMedix Inc. (CRMD) surged 9.47% in pre-market trading on Wednesday following the release of its impressive third-quarter 2025 financial results and an upward revision of its full-year...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CRMD":"CorMedix Inc."},"translate_title":"个股追踪|CorMedix盘前大涨9.47%Q3业绩强劲且指引上调","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRMD":1},"content_text":"Shares of CorMedix Inc. (CRMD) surged 9.47% in pre-market trading on Wednesday following the release of its impressive third-quarter 2025 financial results and an upward revision of its full-year guidance.\nThe biopharma company reported a third-quarter earnings per share (EPS) of $1.26, significantly beating the analyst consensus estimate of $0.65. Net income for the quarter stood at $108.6 million, nearly doubling the expected $54.7 million. CorMedix's strong performance was largely driven by higher-than-anticipated sales of its flagship product, DefenCath, which contributed $88.8 million to the quarter's net revenue of $104.3 million.\nIn light of the robust quarterly performance, CorMedix raised its full-year 2025 pro forma net revenue guidance to a range of $390 million to $410 million. The company also increased its 2025 pro forma adjusted EBITDA guidance to between $220 million and $240 million. This optimistic outlook, coupled with the strong Q3 results, has fueled investor enthusiasm, leading to the significant pre-market stock price jump.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1123083935","isCrawlerRequest":true}